For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .
Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia.
This prospect i ve study was design ed to compare the efficacy of ondansetron with granisetron in terms of complete emesis control and time spent in an ambulatory care setting in children with acute lymphoblastic leukemia ( ALL ) undergoing moderately emetogenic cyclophosphamide-based chemotherapy .  The costs for both treatments are also examined . A total of 33 children ( mean age : 7.8 + /- 4.9 year ) were studied during 66  chemotherapy cycles . Analysis was based on 33 courses of a single oral dose of granisetron and 33 courses of ondansetron incorporating 2 intravenous doses of ondansetron 0.15 mg/kg followed by 1 dose of the same dosage orally . There was no significant difference between the 2 treatments in terms of overall efficacy ( McNemar 's chi-square test ) . Twenty of 33 patients ( 60.6 % ) receiving granisetron and 15 of 33 patients ( 45.5 % ) receiving ondansetron experienced no emesis 24 h after chemotherapy ( p = .227 ) . Boys experienced greater rates of vomiting than did girls despite antiemetic treatment ; however , no apparent reason for the gender discrepancy was noted . Both antiemetic regimens have similar antiemetic efficacy for treating the moderately emetogenic effects associated with cyclophosphamide-based chemotherapy . It is possible that the granisetron regimen may be preferable because it is simpler to administer and more cost-effective
For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .